Welcome to our dedicated page for CureVac N.V. Ordinary Shares news (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on CureVac N.V. Ordinary Shares stock.
CureVac N.V. (NASDAQ: CVAC) is a pioneering biopharmaceutical company based in Germany, known for its groundbreaking work in the field of messenger RNA (mRNA) technology. Founded in 2000 as a spin-off from the University of Tübingen, CureVac has developed a unique position as a leader in mRNA research and development. The company's core technology uses mRNA as a data carrier that instructs the human body to produce its own proteins capable of fighting a wide range of diseases, including cancer, infectious diseases, and rare genetic disorders.
CureVac's proprietary mRNA technology has a broad range of applications. In oncology, the company is developing both off-the-shelf and personalized cancer vaccines. Their off-the-shelf cancer vaccines target tumor antigens shared across different cancer types, while the personalized vaccines are tailored to individual patients based on their unique tumor profiles. CureVac has recently entered a collaboration with The University of Texas MD Anderson Cancer Center to further this mission.
In infectious disease, CureVac has partnered with pharmaceutical giant GSK to develop a suite of prophylactic vaccines. This includes second-generation COVID-19 vaccines and a promising seasonal influenza vaccine program. Recent Phase 2 interim data showed that CureVac's influenza vaccine candidates produce higher geometric mean titers against influenza A strains compared to licensed vaccines, though optimizations are ongoing for influenza B strains. Additionally, a new Phase 2 study has been initiated to further enhance the immune response against the relevant influenza B strain.
Financially, CureVac remains robust, with cash and cash equivalents amounting to €402.5 million at the end of 2023. The company's strategic initiatives, such as organizational redesign and partnerships, aim to extend this runway into the fourth quarter of 2025. As of late, CureVac has also achieved significant milestones in its clinical pipeline, which includes a move to Phase 2 studies for its H5N1 avian flu vaccine candidate and ongoing litigation to defend its intellectual property rights.
Overall, CureVac continues to push the boundaries of mRNA technology, with a deep clinical pipeline and strong collaborations to back its innovative discoveries. For more information, visit their official website at www.curevac.com.
CureVac (NASDAQ:CVAC) appointed Antony Blanc, PhD, as Chief Business Officer and Chief Commercial Officer, effective immediately. Blanc brings extensive experience in biotech and vaccines, previously serving roles at McKinsey & Company and GSK Vaccines. His expertise in RNA research is expected to enhance CureVac's business development and growth. The company is advancing its mRNA-based COVID-19 vaccine, CVnCoV, with promising Phase 1 interim data indicating strong antibody responses. CureVac is also expanding manufacturing capacities to prepare for commercial supply.
CureVac (NASDAQ: CVAC) reported promising interim Phase 1 data for its COVID-19 vaccine candidate, CVnCoV, demonstrating strong antibody responses and T-cell activation. The company secured an agreement with the European Commission to supply 225 million doses, with an option for 180 million more. CureVac reported a cash position of €892 million and revenues of €5.2 million for Q3 2020, marking a 371% increase year-over-year. The company plans to initiate a pivotal Phase 2b/3 trial shortly, aiming to expand its vaccine capabilities and address the ongoing pandemic.
CureVac N.V. (Nasdaq:CVAC) will report its financial results and business updates for Q3 and the first nine months of 2020 on November 30, 2020. A conference call and webcast will occur at 4:00 p.m. CET / 10:00 a.m. EST with details provided for participation. This follows the company's IPO in August 2020, marking its entry into the public market. CureVac focuses on mRNA technology, with a pipeline in vaccines, cancer therapies, and rare diseases. The company has over 500 employees and is headquartered in Tübingen, Germany.
CureVac N.V. (NASDAQ:CVAC) has announced plans to expand its manufacturing capabilities for the COVID-19 vaccine candidate, CVnCoV, aiming for up to 300 million doses in 2021 and 600 million doses in 2022. This initiative involves building a European vaccine manufacturing network with experienced partners to mitigate supply chain risks. The company is in the process of finalizing technology transfers and establishing partnerships with various CDMO firms across Europe, enhancing production resilience.
CureVac (Nasdaq:CVAC) announced that the European Commission will authorize an Advanced Purchase Agreement for its mRNA-based COVID-19 vaccine candidate, CVnCoV. The contract encompasses 225 million initial doses, with an option for an additional 180 million doses. An upfront payment will support advanced clinical development and ramp-up of manufacturing capabilities. CVnCoV is undergoing pivotal Phase 2b/3 clinical trials, following promising Phase 1 data indicating strong immune responses. CureVac aims to provide equitable access to its vaccine globally.
CureVac N.V. (NASDAQ: CVAC) has published detailed interim Phase 1 data for its COVID-19 vaccine candidate, CVnCoV, following positive topline results reported on November 2, 2020. The data highlights that CVnCoV was well tolerated across doses (2-12μg) and induced robust antibody responses, mimicking immune responses in recovered COVID-19 patients. The manuscript is available on medRxiv. A conference call is scheduled for today at 5 p.m. CET to discuss the data further, with plans for a pivotal Phase 2b/3 trial by year-end.
CureVac N.V. (NASDAQ:CVAC) reported positive interim data from its Phase 1 study of CVnCoV, a COVID-19 vaccine candidate. The vaccine demonstrated a balanced immune response, inducing strong binding and neutralizing antibodies, alongside initial T cell activation. Results showed that the immune response is comparable to that of recovered COVID-19 patients. With the 12µg dose showing the most promise, CureVac plans to advance to a pivotal Phase 2b/3 clinical trial by the end of 2020, having already administered doses to over 250 participants.
CureVac N.V. (NASDAQ: CVAC) reported positive preclinical results for its COVID-19 vaccine candidate, CVnCoV. The vaccine induced strong antibody and T cell responses in animal models, effectively protecting against SARS-CoV-2 with a favorable safety profile. Notably, hamsters showed significant reduction in viral load and complete lung protection after vaccination. CureVac continues its Phase 1 and 2a clinical trials, with interim data expected soon. The company aims to scale up production capabilities for potential commercial supply.
CureVac N.V. (NASDAQ:CVAC) has initiated its Phase 2a clinical trial for the COVID-19 vaccine candidate, CVnCoV, with the first participant dosed in Peru and Panama. Enrolling 690 participants, the trial targets both younger adults (18-60 years) and older adults (61+ years). The study aims to confirm safety and reactogenicity while assessing the immune response in a high COVID-19 incidence area. Results are expected by Q4 2020. This trial follows the positive preliminary data from an ongoing Phase 1 study in Europe, and a larger Phase 2b/3 trial is planned for later this year.
CureVac (NASDAQ:CVAC) has been notified by the German Federal Ministry of Education and Research of an expected funding of up to 252 million euros to support the development of its COVID-19 vaccine candidate, CVnCoV. This funding will aid in accelerating research and expanding production capacity. The grant will provide 103 million euros in 2020 and 149 million euros in 2021, contingent on meeting milestones. CEO Franz-Werner Haas emphasized the importance of this financial support to develop a safe and effective vaccine quickly.
FAQ
What is the current stock price of CureVac N.V. Ordinary Shares (CVAC)?
What is the market cap of CureVac N.V. Ordinary Shares (CVAC)?
What does CureVac N.V. do?
Where is CureVac headquartered?
Who are CureVac's notable partners?
What are CureVac's recent achievements in vaccine development?
How is CureVac financially positioned?
What is the role of mRNA in CureVac's technology?
What are CureVac's focus areas in oncology?
What are some challenges CureVac has faced?
What recent collaborations has CureVac entered into?
What is CureVac's latest financial result?
